DATASHEET
Host:
Rabbit
Target Protein:
GCNT2
Immunogen Range:
151-250/400
Clonality:
Polyclonal
Isotype:
IgG
Entrez Gene:
2651
Source:
KLH conjugated synthetic peptide derived from human GCNT2
Purification:
Purified by Protein A.
Storage Buffer:
0.01M TBS(pH7.4) with 1% BSA, 0.02% Proclin300 and 50% Glycerol.
Storage:
Shipped at 4C. Store at -20C for one year. Avoid repeated freeze/thaw cycles.
Background:
Belonging to the glycosyltransferase 14 family, GCNT2 (glucosaminyl (N-acetyl) transferase 2, I-branching enzyme (I blood group)), also known as II, N-acetylglucosaminyltransferase, IGNT, CCAT, ULG3, GCNT5, GCNT2C or NACGT1, is a 400 amino acid glycosyltransferase that localizes to the Golgi apparatus. Other members of the glycosyltransferase 14 family include GCNT1, GCNT3, GCNT4, GCNT6 and GCNT7. A single-pass type II membrane protein, GCNT2 functions as a branching enzyme known as beta-1,6-N-acetylglucosaminyltransferase, which converts fetal i antigen to adult I antigen in erythrocytes during embryonic development. With expression levels increasing significantly during oncogenesis and development, GCNT2 is found at highest levels in adult prostate and fetal brain, and is found at low levels in heart, small intestine, colon, brain, pancreas and kidney.
VALIDATION IMAGES
Lane 1: A549 cell lysates probed with Rabbit Anti-GCNT2 Polyclonal Antibody, Unconjugated (bs-13316R) at 1:300 overnight at 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:5000 for 90 min at RT.
Mouse placenta lysates probed with Rabbit Anti-GCNT Polyclonal Antibody, Unconjugated (bs-13316R) at 1:300 overnight at 4˚C. Followed by conjugation to secondary antibody (bs-0295G-HRP) at 1:500 for 90 min at RT.
Formalin-fixed and paraffin embedded human prostate labeled with Anti-GCNT2 Polyclonal Antibody, Unconjugated (bs-13316R) at 1:200 followed by conjugation to the secondary antibody and DAB staining
Lane 1: Rat Cerebrum tissue lysates; Lane 2: Human A431 cell lysates probed with GCNT2 Polyclonal Antibody, Unconjugated (bs-13316R) at 1:1000 dilution and 4°C overnight incubation. Followed by conjugated secondary antibody incubation at 1:20000 for 60 min at 37˚C.